NASDAQ · IMRX
Immuneering Corporation
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
Price chart by TradingView
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarThe next earnings date for IMRX has not been announced yet.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Dec 2026 | $-0.31 | $-0.28 | $-0.34 | 3 |
| Mar 2027 | $-0.35 | $-0.35 | $-0.35 | 1 |
| Jun 2027 | $-0.37 | $-0.37 | $-0.37 | 1 |
| Sep 2027 | $-0.40 | $-0.40 | $-0.40 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Fintel · RTTNews · Zacks · BNK Invest- Fintel · Oct 30, 1:08 AM EDTImmuneering Corporation Reports Third Quarter 2026 Financial Results and Provides Business UpdatesImmuneering Corporation reported its financial results for the third quarter ended September 30, 2026, and provided clinical updates. The company announced that follow-up in its Phase 2 trial of atebimetinib in combination with modified gemcitabine/nab-paclitaxel in first-line pa
- RTTNews · Aug 27, 8:16 AM EDTImmuneering Reaffirms First-Line Pancreatic Cancer Focus Following FDA Nod For Rasonque(RTTNews) – Immuneering (IMRX), a late-stage clinical oncology company, issued a statement highlighting its focus on the first-line metastatic pancreatic cancer setting following the FDA's approval of Revolution Medicines' (RVMD) Rasonque (daraxonrasib), for previously treated me
- Zacks · Jul 15, 12:00 PM EDTImmuneering (IMRX) Upgraded to Buy: Here's What You Should KnowImmuneering (IMRX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- RTTNews · Jun 15, 7:55 AM EDTImmuneering Corp Appoints Andrew Gengos As CFO(RTTNews) – Immuneering Corporation (IMRX), a late-stage clinical oncology company, Monday announced that it has appointed Andrew Gengos as Chief Financial Officer, effective July 16.
- Zacks · Jun 12, 9:48 AM EDTIMRX Begins Dosing in Phase III Pancreatic Cancer Study, Stock UpImmuneering stock rises after dosing the first patient in a pivotal phase III study of atebimetinib plus mGnP for first-line metastatic pancreatic cancer.
- RTTNews · Jun 2, 5:16 AM EDTImmuneering Presents Promising Phase 2a Data For Atebimetinib In Pancreatic Cancer; Shares Drop 22%(RTTNews) – Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Monday reported efficacy results of the Phase 2a trial evaluating Atebimetinib in combination with modified gemcitabine nab paclitaxel (mGnP) in treating first-line metastatic pancreatic ductal
- RTTNews · May 31, 10:29 PM EDTTop Biotech Gainers: REPL On Track, SNSE Awaits Phase 2 Data, Keep An Eye On CCCC, IMRX Soars(RTTNews) – Friday's Top Gainers included Replimune, which is preparing to resubmit its Biologics License Application (BLA) for RP1 in advanced melanoma; Clearmind Medicine, which strengthened its global intellectual property portfolio through a Japanese patent filing covering a
- RTTNews · May 22, 3:55 AM EDTImmuneering Announces Phase 2a Median OS Of 17 Months For Atebimetinib In Pancreatic Cancer(RTTNews) – Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Thursday announced encouraging initial data from the Phase 2a trial for Atebimetinib in combination with mGnP for treating metastatic pancreatic cancer.
- RTTNews · Apr 22, 4:40 AM EDTImmuneering To Present New Phase 2a Data For Atebimetinib In Treating Pancreatic Cancer On June 1(RTTNews) – Immuneering Corporation (IMRX), a late-stage clinical oncology company, is expected to present updated data from its Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel in treating pancreatic cancer at the annual meeting of the Ameri
- RTTNews · Apr 21, 2:34 AM EDTImmuneering Presents Encouraging CtDNA Data For Atebimetinib In Treating Cancer(RTTNews) – Immuneering Corporation (IMRX), a late-stage clinical oncology company, on Monday presented promising genetic data from clinical trials of cancer drug Atebimetinib at the annual meeting of the American Association of Cancer Research (AACR).
- BNK Invest · Jan 15, 1:58 PM ESTThursday 1/15 Insider Buying Report: IMRX, DLPNBargain hunters are wise to pay careful attention to insider buying, because although there are many various reasons for an insider to sell a stock, presumably the only reason they would use their hard-earned cash to make a purchase, is that they expect to make money. Today we
- RTTNews · Jan 8, 2:30 AM ESTIMRX Reports 12-Month Survival Of 64% In First-Line Pancreatic Cancer Patients; But Stock Plunges(RTTNews) – Immuneering Corp. (IMRX) announced positive updated results from its ongoing Phase 2a trial of Atebimetinib in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line metastatic pancreatic cancer. Despite the encouraging results, the stock plunged ov
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Company profile by TradingView
Financials
Loading fundamental data…
Fundamental data by TradingView
More headlines
More stories for Immuneering Corporation from TradingView. Coverage varies.
Loading related news…
Related news by TradingView
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.